initial public offerings (IPOs) trading on American exchanges

Sunday, January 26, 2014

Receptos, Inc.(RCPT) began trading on the NASDAQ on 6 May 2013

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics for immune disorders. Its lead product includes RPC1063, an oral sphingosine 1-phosphate 1 receptor modulator that is in Phase II portion of Phase II/III studies for the treatment of relapsing multiple sclerosis; and is in Phase II studies to treat ulcerative colitis. The company's products also comprise RPC4046, a monoclonal antibody, which is in Phase II studies for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. It is also developing glucagon-like peptide-1 receptor small molecule positive allosteric modulators that are in Preclinical studies for the treatment of Type 2 Diabetes. The company was formerly known as Receptor Pharmaceuticals, Inc. and changed its name to Receptos, Inc. in May 2009. Receptos, Inc. was founded in 2008 and is headquartered in San Diego, California.

weekly chart

No comments:

Post a Comment